Biologic Evaluation of Renal Toxicity of Cisplatin and Ifosfamide (TOXIPLAT)
- Identify and evaluate the early biomarkers of renal toxicity in patients with solid
tumors treated with cisplatin and ifosfamide.
- Correlate the modification of biomarker studies and blood concentrations of cisplatin.
OUTLINE: Patients receive standard chemotherapy comprising cisplatin and/or ifosfamide.
Blood and urine samples are collected on days 1 and 2 (or day 3 if receiving ifosfamide
only) during the first 3 courses. Samples are analyzed to determine plasma concentrations of
residual cisplatin and to obtain urinary-protein profiles to measure renal toxicity.
Allocation: Non-Randomized, Primary Purpose: Treatment
Evolution of different biomarkers
Christine Chevreau-Dalbianco, MD
Institut Claudius Regaud